Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AWHNASDAQ:MYMDNYSE:NAVBNASDAQ:NYMX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAWHAspira Women's Health$0.08-12.5%$0.08$0.08▼$1.73$2.44M2.011.49 million shs4.31 million shsMYMDMyMD Pharmaceuticals$0.14-1.6%$0.18$1.75▼$63.90$326K2.15134,123 shs7.84 million shsNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$20K1.78,490 shs820 shsNYMXNymox Pharmaceutical$0.34$0.17▼$0.74$18.10M0.6494,622 shs932,700 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAWHAspira Women's Health0.00%0.00%0.00%-22.05%-93.83%MYMDMyMD Pharmaceuticals-1.57%-1.57%-21.10%-61.67%-92.72%NAVBNavidea Biopharmaceuticals0.00%0.00%-71.43%-50.00%0.00%NYMXNymox Pharmaceutical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAWHAspira Women's Health0.8359 of 5 stars3.50.00.00.00.00.00.0MYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANYMXNymox PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAWHAspira Women's Health 3.00Buy$5.506,607.32% UpsideMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ANYMXNymox Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAWHAspira Women's Health$9.18M0.27N/AN/A($0.23) per share-0.36MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ANAVBNavidea Biopharmaceuticals$8.13K2.46N/AN/AN/A∞NYMXNymox PharmaceuticalN/AN/AN/AN/A($0.01) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAWHAspira Women's Health-$16.69M-$0.98N/A∞N/A-165.07%N/A-267.23%8/11/2025 (Estimated)MYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ANYMXNymox Pharmaceutical-$6.58M-$0.04N/AN/AN/AN/A-1,589.50%-117.25%N/ALatest NYMX, AWH, MYMD, and NAVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024AWHAspira Women's Health-$0.21-$0.08+$0.13-$0.08$3.00 million$2.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAWHAspira Women's Health$1.041,268.29%N/AN/A N/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ANYMXNymox PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAWHAspira Women's HealthN/A0.750.70MYMDMyMD PharmaceuticalsN/A0.620.62NAVBNavidea BiopharmaceuticalsN/AN/AN/ANYMXNymox PharmaceuticalN/A0.190.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAWHAspira Women's Health12.19%MYMDMyMD Pharmaceuticals9.64%NAVBNavidea Biopharmaceuticals0.01%NYMXNymox Pharmaceutical1.14%Insider OwnershipCompanyInsider OwnershipAWHAspira Women's Health4.30%MYMDMyMD Pharmaceuticals2.12%NAVBNavidea Biopharmaceuticals43.68%NYMXNymox Pharmaceutical54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAWHAspira Women's Health11029.76 million16.92 millionNo DataMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableNYMXNymox Pharmaceutical390.51 million41.64 millionOptionableNYMX, AWH, MYMD, and NAVB HeadlinesRecent News About These CompaniesNymox Announces Filing of Annual ReportAugust 31, 2024 | markets.businessinsider.comNymox Annual ReportJuly 20, 2024 | finance.yahoo.comLatest challenges in pharmaceutical tradeFebruary 16, 2024 | pharmaphorum.comPNymox December 27 Message to ShareholdersDecember 27, 2023 | markets.businessinsider.comNymox Pharmaceutical Corporation: Nymox December 27 Message to ShareholdersDecember 27, 2023 | finanznachrichten.deNymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and OthersNovember 30, 2023 | finance.yahoo.comNymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 22, 2023 | finanznachrichten.de$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 21, 2023 | markets.businessinsider.comNymox drama heightens as biotech sues AscellaHealth for $250M in damagesNovember 10, 2023 | fiercebiotech.comFNymox Pharmaceutical Corporation Sues AscellaHealth For $250 MillionNovember 9, 2023 | markets.businessinsider.comThe Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special MeetingNovember 6, 2023 | finance.yahoo.comNYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023November 3, 2023 | financialpost.comFNotice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder MeetingOctober 27, 2023 | benzinga.comNymox Pharmaceutical Corporation: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For ReviewOctober 26, 2023 | finanznachrichten.deThe Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special MeetingOctober 24, 2023 | aa.com.trAThe Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical ShareholdersOctober 11, 2023 | finance.yahoo.comBahamas Supreme Court Rules in Favor of Committee…October 6, 2023 | pharmiweb.comPBahamas Supreme Court Rules in Favor of Committee to Restore Nymox Shareholder Value: Orders Shareholder Meeting, Grants Injunction Freezing CEO SharesOctober 6, 2023 | businesswire.comNymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX ...September 27, 2023 | bakersfield.comBNymox Pharmaceutical Corporation (NYMXF)September 26, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNYMX, AWH, MYMD, and NAVB Company DescriptionsAspira Women's Health NASDAQ:AWH$0.08 -0.01 (-12.49%) As of 04/16/2025Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.MyMD Pharmaceuticals NASDAQ:MYMD$0.14 0.00 (-1.57%) As of 06/25/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Navidea Biopharmaceuticals NYSE:NAVB$0.0002 0.00 (0.00%) As of 06/26/2025 01:22 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Nymox Pharmaceutical NASDAQ:NYMXNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
